All In Biotech

Drug Trial Radar · NCT07250737

Managed Access Program for Del-zota in Participants With DMD Mutations Amenable to Exon 44 Skipping

Managed Access to Investigational Use of AOC 1044 in Participants With DMD Mutations Amenable to Exon 44 Skipping

Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Available

Status

Available

Enrollment

Not stated

Start

Not stated

Primary completion

Not stated

Sponsor

Lead sponsor
Avidity Biosciences, Inc.Industry
Sponsor type
Industry
Collaborators
Clinigen Healthcare Limited
First posted
Nov 26, 2025

More drug trials from this sponsor

Design

Study type
Expanded access
Who can join
Male only, from 2 years

Summary

As written by the sponsor on the registry.

The purpose of this Managed Access Program is to allow access to delpacibart zotadirsen (AOC 1044) for eligible patients diagnosed with DMD mutations amenable to exon 44 skipping. The patient's Administering Physician should follow the suggested treatment guidelines and comply with all local health authority regulations.

Conditions

  • Muscular Disorders, Atrophic
  • Muscular Diseases
  • Musculoskeletal Diseases
  • Neuromuscular Diseases
  • Nervous System Diseases
  • Genetic Diseases, Inborn
  • Genetic Diseases, X-Linked
  • Muscular Dystrophies
  • Muscular Dystrophy, Duchenne

Interventions

  • delpacibart zotadirsenDrug

    Del-zota is administered as an IV infusion every 6 weeks. Doses are administered based on body weight.

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

22 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama

    Birmingham, Alabama · Available

  • Arkansas Children's Hospital

    Little Rock, Arkansas · Available

  • UCI Alpha Clinic

    Irvine, California · Available

  • Lucille Packard Children's Hospital at Stanford

    San Carlos, California · Available

  • UC San Diego Health

    San Diego, California · Available

  • Connecticut Children's Medical Center

    Hartford, Connecticut · Available

  • Rare Disease Research

    Kissimmee, Florida · Available

  • Nicklaus Children's Hospital

    Miami, Florida · Available

  • Rare Disease Research

    Atlanta, Georgia · Available

  • University of Kansas Medical Center

    Kansas City, Kansas · Available

  • UMass Memorial Health Care

    Worcester, Massachusetts · Available

  • Gillette Children's

    Saint Paul, Minnesota · Available

  • Washington University

    St Louis, Missouri · Available

  • Rare Disease Research

    Iselin, New Jersey · Available

  • Rare Disease Research

    Hillsborough, North Carolina · Available

  • Nationwide Children's Hospital

    Columbus, Ohio · Available

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania · Available

  • University of Pennsylvania

    Philadelphia, Pennsylvania · Available

  • Prisma Health-Midlands Children's Hospital

    Columbia, South Carolina · Available

  • Neurology & Neuromuscular Care Center

    Flower Mound, Texas · Available

  • UTHealth

    Houston, Texas · Available

  • University of Vermont Medical Center

    Burlington, Vermont · Available

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.